Findings

What do systematic reviews say?

104 questions · 110 findings · 13 reviews

No studies found 14 · 12.7%GRADE not reported 4 · 3.6%Very low 34 · 30.9%Low 25 · 22.7%Moderate 29 · 26.4%High 4 · 3.6%

OS not reported · newly diagnosed or relapsed patients with CLL

The review found no eligible studies for this question.

1 finding from 1 review

Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PFS not reported · newly diagnosed or relapsed patients with CLL

1 finding from 1 review

Time to next treatment · newly diagnosed or relapsed patients with CLL

1 finding from 1 review

CRR · newly diagnosed or relapsed patients with CLL

The intervention showed no clear difference in CRR (moderate certainty).

1 finding from 1 review

Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia 2012 · Cochrane Headline outcomes only
RR 1.18 [0.93, 1.49]
2 studies · 170 participants
Moderate